| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2174/138920008786049302 |
| P698 | PubMed publication ID | 18855611 |
| P50 | author | Charlie Xue | Q37839010 |
| P2093 | author name string | Min Tian | |
| Wei Duan | |||
| Eli Chan | |||
| Shu-Feng Zhou | |||
| Chun Guang Li | |||
| Yao-Min Du | |||
| Yuan Ming Di | |||
| Xinsheng Lai | |||
| Jian-Cheng Wang | |||
| Vivian Deh-Wei Chow | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 738-784 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Current Drug Metabolism | Q15724618 |
| P1476 | title | Clinical pharmacogenetics and potential application in personalized medicine | |
| P478 | volume | 9 |
| Q37628680 | (13)C breath tests in personalized medicine: fiction or reality? |
| Q37734926 | A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy |
| Q37494640 | Application of mechanism-based CYP inhibition for predicting drug-drug interactions |
| Q44313587 | Assessment of heritable genetic effects using new genetic tools and sentinels in an era of personalized medicine |
| Q40267083 | CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity |
| Q33849298 | CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? |
| Q28544111 | CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug |
| Q37657540 | Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. |
| Q37970709 | Clinically-relevant anticancer-antidepressant drug interactions. |
| Q38199740 | Considerations for rare variants in drug metabolism genes and the clinical implications |
| Q35375045 | Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance |
| Q42970803 | Current concepts in the genetic diagnostics of rheumatoid arthritis. |
| Q30474378 | Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare |
| Q35915497 | Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy |
| Q34139962 | Dissecting variability in responses to cancer chemotherapy through systems pharmacology |
| Q52838248 | Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro. |
| Q28744127 | Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study |
| Q34002029 | Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy |
| Q37564562 | Emerging drugs for major depressive disorder |
| Q37818297 | Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. |
| Q47707268 | Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences |
| Q55266735 | Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. |
| Q36044627 | GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy |
| Q41908761 | Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis |
| Q34564576 | Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis |
| Q35049590 | Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate |
| Q37924890 | Genetic variations in multiple myeloma II: association with effect of treatment |
| Q37998525 | Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments |
| Q38731965 | Global genetic variation of select opiate metabolism genes in self-reported healthy individuals |
| Q42730547 | Hepatocyte CYP2B6 Can Be Expressed in Cell Culture Systems by Exerting Physiological Levels of Shear: Implications for ADME Testing |
| Q35005999 | Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy |
| Q39385024 | Increasing the reach of forensic genetics with massively parallel sequencing |
| Q43049836 | Individual oral therapy with immediate release and effervescent formulations delivered by the solid dosage pen. |
| Q37378059 | Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. |
| Q37874869 | Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases |
| Q36036395 | Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Ac |
| Q47649550 | Interpersonal factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 genotypes enough for us to make a clinical decision? |
| Q50072065 | Introducing personalized health for the family: the experience of a single hospital system |
| Q36095613 | Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy. |
| Q39946483 | Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians |
| Q34994964 | New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme |
| Q37944353 | Pain, analgesia and genetics. |
| Q38027858 | Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery |
| Q42793934 | Personalized medicine and tobacco-related health disparities: is there a role for genetics? |
| Q35172002 | Pharmacogenetics in Ghana: reviewing the evidence |
| Q38003703 | Pharmacogenetics of chemotherapy efficacy in breast cancer |
| Q37461474 | Pharmacogenetics of vitamin K antagonists: useful or hype? |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37592250 | Pharmacogenomics and therapeutic strategies for dementia |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q42856203 | Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution |
| Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
| Q43244977 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. |
| Q28482330 | Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum |
| Q88220701 | Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy |
| Q90650446 | Prevalence of ABCC3-1767G/A polymorphism among patients with antiretroviral-associated hepatotoxicity |
| Q34702564 | Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes |
| Q35015993 | Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. |
| Q34676948 | The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity |
| Q90631104 | The brain-placental axis: Therapeutic and pharmacological relevancy to pregnancy |
| Q37913976 | The pharmacogenetics of antiplatelet agents: towards personalized therapy? |
| Q35085937 | The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians. |
| Q39991278 | Understanding Personalized Medicine in Rheumatoid Arthritis: A Clinician's Guide to the Future |
| Q55182205 | Using Regularization to Infer Cell Line Specificity in Logical Network Models of Signaling Pathways. |
Search more.